Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tizanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 6/20 | 0.70 |
| ▸ | ADRA2B known ✓ | P18089 | 5/20 | 0.70 |
| ▸ | ADRA2C known ✓ | P18825 | 5/20 | 0.70 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.70 |
| ▸ | HRH2 | P25021 | 2/20 | 0.70 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.42 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tizanidine SCHEMBL2473401 | 0.91 | ADRA2A (0.80) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2471060 | 0.90 | ADRA2A (0.79) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2472595 | 0.87 | ADRA2A (0.80) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL6472652 | 0.82 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Stearic Acid SCHEMBL4344851 | 0.82 | ADRA2A (0.62) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2471445 | 0.82 | ADRA2A (0.86) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2469048 | 0.81 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL18550639 | 0.79 | ADRA2A (0.70) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL13724114 | 0.77 | ADRA2A (0.63) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Methocarbamol SCHEMBL2721599 | 0.72 | ADRA2A (0.57) | ADRA2AADRA2BADRA2CADRA1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107759582-B | Preparation method of novel central skeletal muscle relaxant | 四川科瑞德制药股份有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-107759582-A | A kind of preparation method of new central skeletal muscle relaxant | 四川科瑞德制药股份有限公司 | 2018-03-06 | — | — | CN | disclosed |
| EP-2370433-B1 | A METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE | FARMAK A S (CZ) | 2014-05-14 | — | — | EP | disclosed |
| US-8487113-B2 | Method for the preparation of tizanidine hydrochloride | FARMAK, A.S. (CZ) | 2013-07-16 | — | — | US | disclosed |
| US-20110263863-A1 | METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE | FARMAK, A.S. (CZ) | 2011-10-27 | — | — | US | disclosed |
| EP-2370433-A2 | A METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE | Farmak, A.S. (CZ) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010069280-A2 | A METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE | FARMAK, A.S. (CZ) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263863-A1 | METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE | HRH2, HNMT, QDPR | ADRA2A 338/4885ADRA2B 429/4885ADRA2C 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.